Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 1998

View Archived Issues

YM-337 shows therapeutic potential for the treatment of coronary thrombosis

Company Profile: Rigel

Resveratrol has a direct antiproliferative effect against breast cancer cells

Rights to bgh gene tool available from RCT

Sequus and Faulding sign marketing agreement for Amphotec

Company Profile: AEterna

Connetics: Q1 1998 highlights

Transgene: Q1 1998 highlights

Bionutrics to acquire Lipoprotein and its cholesterol-lowering drug candidate

Genset: Q1 1998 highlights

Purepac to market generic etodolac 500-mg tablets

BCX-140, an aromatic inhibitor of influenza neuraminidase

Zadaxin decreases formation of lung tumors in mice

IntraDose injectable gel shows promise in phase I/II

Azimilide: a unique new antiarrhythmic agent in phase III development

FDA grants approval for pivotal clinical trial of Repel

Enzo, Hadassah University collaborate on immunomodulating technology

High priority given to linezolid development at Pharmacia & Upjohn

Akorn launches generic cromolyn sodium

First market introduction for basiliximab

Selective somatostatin receptor antagonist reported for pancreatic disorders

Therapeutic Antibodies seeks FDA approval for antivenom product

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

Novartis begins phase III trial with Aredia in prostate cancer patients

Ligand to merge with Seragen and acquire Marathon; acquires fusion toxin rights from Lilly

Immune Network Research reports on progress of primate study evaluating 1F7 for HIV

Pharmacia & Upjohn submits NDA for Edronax

XR-9576 enters clinical testing

IRL-3630: a bifunctional ET antagonist for respiratory ailments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...